title: Noopept normalizes parameters of the incretin system in rats with experimental diabetes.
abstract: Experiments on adult Wistar rats with streptozotocin-induced diabetes showed that antihyperglycemic activity of an original nootropic and neuroprotective drug Noopept (N-phenylacetyl-L-prolylglycine ethyl ester) is more pronounced under conditions of oral application than after intraperitoneal injection. These data provided a basis for studying the effect of Noopept on major indexes of the incretin system. Streptozotocin was shown to decrease the concentrations of incretin GLP-1 and insulin in the blood. Noopept had a normalizing effect on these parameters. This influence of Noopept was not related to the inhibition of a major enzyme metabolizing incretins (dipeptidyl peptidase IV). A reference drug sitagliptin also increased the contents of incretins and insulin, which was associated with the inhibition of dipeptidyl peptidase IV. It is known that GLP-1 increases NGF expression in the insular system. Our results suggest that the increase in incretin activity contributes to the antiapoptotic effect of Noopept on pancreatic β cells. The mechanism for an increase in blood GLP-1 level after oral application of Noopept requires further investigations.
authors: V. V. Zakusov Research Institute of Pharmacology, the Russian Academy of Medical Sciences, Moscow, Russia, rita.ostrovskaya@gmail.com.
authors: R U
authors: RU
authors: Ostrovskaya
authors: N N
authors: NN
authors: Zolotov
authors: I V
authors: IV
authors: Ozerova
authors: E A
authors: EA
authors: Ivanova
authors: I G
authors: IG
authors: Kapitsa
authors: K V
authors: KV
authors: Taraban
authors: A M
authors: AM
authors: Michunskaya
authors: T A
authors: TA
authors: Voronina
authors: T A
authors: TA
authors: Gudasheva
authors: S B
authors: SB
authors: Seredenin
mesh_terms: D000818:Animals; D001786:Blood Glucose; D003921:Diabetes Mellitus, Experimental / Q000097:blood / Q000188:drug therapy*; D004151:Dipeptides / Q000494:pharmacology*; D018819:Dipeptidyl Peptidase 4 / Q000097:blood; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000494:pharmacology; D004353:Drug Evaluation, Preclinical; D052216:Glucagon-Like Peptide 1 / Q000097:blood; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D054795:Incretins / Q000502:physiology*; D007328:Insulin / Q000097:blood; D008297:Male; D010179:Pancreas / Q000187:drug effects / Q000473:pathology; D011719:Pyrazines / Q000494:pharmacology; D017208:Rats, Wistar; D000068900:Sitagliptin Phosphate; D014230:Triazoles / Q000494:pharmacology
chemical_list: D001786:Blood Glucose; D004151:Dipeptides; D054873:Dipeptidyl-Peptidase IV Inhibitors; D007004:Hypoglycemic Agents; D054795:Incretins; D007328:Insulin; D011719:Pyrazines; D014230:Triazoles; C103871:ethyl phenylacetyl-Pro-Gly; D052216:Glucagon-Like Peptide 1; D018819:Dipeptidyl Peptidase 4; D000068900:Sitagliptin Phosphate